Irritable Bowel Syndrome With Constipation Clinical Trial
Official title:
An Evaluation of Cultured Milk Drink on Immune Status of Patients With Constipation Predominant Irritable Bowel Syndrome
Our previous work on the use of probiotics improved the clinical symptoms in irritable bowel syndrome with constipation-predominant. This study would like to explore further use of probiotics in the immune system of the patients with irritable bowel syndrome.
This is a case control study involving participants who fulfilled the Rome III criteria for constipation-predominant irritable bowel syndrome. The patients were recruited from the Gastroenterology clinic at Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur. A total of 165 participants were recruited based on probability (power) of 0.8 and Type I error was set at 0.05. The investigators included healthy participants above 18 years old. Those less than 18 years old; constipation due to other medical illnesses such as diabetes mellitus, inflammatory bowel disease, hypothyroidism, colorectal cancer, neurological diseases, major depression, lactose intolerance, pregnancy, breastfeeding women and must not be on chronic opioids or anti- depressants were excluded. Participants must not consume any antibiotics, probiotic, prebiotic, symbiotic and/or laxatives less than two weeks before recruitment. Participants were required to consume three bottles of 125 ml cultured milk drink daily for 30 days. Each bottle contains 10^9 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose. Cold chain was maintained below 10°C during storage, transportation and distribution. Prior to consumption of the cultured milk drinks, fecal and blood samples from the participants were obtained to determine their baseline fecal pH and serum cytokines level respectively. Each of the participants answered a food frequency questionnaire to assess their dietary profile (data are not presented in this paper) and the Garrigues Questionnaire to evaluate their clinical symptoms and physical activity. The same parameters were taken following 30 days of cultured milk drinks' consumption. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00730171 -
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
|
Phase 3 | |
Completed |
NCT00215566 -
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
|
Phase 2 | |
Completed |
NCT00765999 -
An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
|
Phase 3 | |
Completed |
NCT02559206 -
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
|
Phase 2 | |
Recruiting |
NCT05646186 -
Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT04026113 -
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
|
Phase 3 | |
Recruiting |
NCT05519683 -
Home Transcutaneous Electrical Acustimulation (TEA)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04166058 -
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
|
Phase 3 | |
Completed |
NCT05164861 -
Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations
|
N/A | |
Completed |
NCT04968652 -
IBS-C Questionnaire Study
|
||
Completed |
NCT02590432 -
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
|
Phase 4 | |
Terminated |
NCT02559817 -
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
|
Phase 2 | |
Recruiting |
NCT05796388 -
A Study of Virtual Reality and Linaclotide for IBS-C
|
N/A | |
Completed |
NCT00380250 -
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
|
Phase 3 | |
Completed |
NCT03054506 -
The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
|
N/A | |
Recruiting |
NCT04214470 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
|
||
Not yet recruiting |
NCT06219707 -
Electro-acupuncture for Irritable Bowel Syndrome With Constipation
|
N/A | |
Recruiting |
NCT03596905 -
Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)
|
Phase 2 | |
Completed |
NCT04132804 -
Effect of Tai Chi as Treatment for IBS-C
|
N/A | |
Completed |
NCT00938717 -
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
|
Phase 3 |